Your browser doesn't support javascript.
loading
[MSProDiscuss - Development of a Digital Anamnesis Tool to Identify Disease Progression in Multiple Sclerosis]. / MSProDiscuss ­ Entwicklung eines digitalen Tools zur standardisierten Patientenanamnese, um Progredienz bei Multipler Sklerose zu identifizieren.
Inojosa, Hernan; Akgün, Katja; Haacke, Katrin; Ziemssen, Tjalf.
Afiliação
  • Inojosa H; Zentrum für klinische Neurowissenschaften, Klinik für Neurologie, Technische Universität Dresden/ Universitätsklinikum Dresden, Dresden, Deutschland.
  • Akgün K; Zentrum für klinische Neurowissenschaften, Klinik für Neurologie, Technische Universität Dresden/ Universitätsklinikum Dresden, Dresden, Deutschland.
  • Haacke K; Zentrum für klinische Neurowissenschaften, Klinik für Neurologie, Technische Universität Dresden/ Universitätsklinikum Dresden, Dresden, Deutschland.
  • Ziemssen T; Zentrum für klinische Neurowissenschaften, Klinik für Neurologie, Technische Universität Dresden/ Universitätsklinikum Dresden, Dresden, Deutschland.
Fortschr Neurol Psychiatr ; 89(7-08): 374-381, 2021 Jul.
Article em De | MEDLINE | ID: mdl-33723837
ABSTRACT
During the course of Multiple Sclerosis (MS), most patients with relapsing remitting MS (RRMS) convert to secondary progressive MS (SPMS), an MS-phenotype associated with a steady deterioration of functional ability independent from relapses and worsened prognosis. Due to the heterogeneity of this conversion, SPMS-diagnosis is often challenging and made retrospectively with a delay of several years. In this review, we first discuss advantages and limitations of screening tools for early SPMS-detection such as the SPMS nomogram, the MS prediction score, and the best SPMS definition approach. These screening tools might help to shorten the phase of diagnostic uncertainty. We then focus on the development of MSProDiscuss, a novel web-based tool that helps the treating neurologist to systematically assesses parameters highly relevant for SPMS-conversion during routine anamnesis. These parameters involve disease activity, symptoms, and impacts of the patient's overall symptoms. In a recent validation study, MSProDiscuss demonstrated high sensitivity, specificity, and interrater reliability. MSProDiscuss does not impose an additional time burden on the treating neurologist and its results are easy to interpret by a simple traffic light system. In first usability tests, it was therefore assessed as a helpful tool for the clinical routine. The early detection of clinically significant progression by diagnostic tools such as MSProDiscuss could open a time-window for therapeutic interventions.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Crônica Progressiva / Esclerose Múltipla Recidivante-Remitente / Esclerose Múltipla Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: De Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Crônica Progressiva / Esclerose Múltipla Recidivante-Remitente / Esclerose Múltipla Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: De Ano de publicação: 2021 Tipo de documento: Article